The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

Christopher D. Gocke, Douglas E. Gladstone

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab'. Together they form a unique fingerprint.